132 related articles for article (PubMed ID: 36281599)
21. Sequential hormonal therapy for metastatic breast cancer after adjuvant tamoxifen or anastrozole.
Carlson RW; Henderson IC
Breast Cancer Res Treat; 2003; 80 Suppl 1():S19-26; discussion S27-8. PubMed ID: 14535531
[TBL] [Abstract][Full Text] [Related]
22. Adherence trajectories of adjuvant endocrine therapy in the five years after its initiation among women with non-metastatic breast cancer: a cohort study using administrative databases.
Lambert-Côté L; Bouhnik AD; Bendiane MK; Bérenger C; Mondor M; Huiart L; Lauzier S
Breast Cancer Res Treat; 2020 Apr; 180(3):777-790. PubMed ID: 32086655
[TBL] [Abstract][Full Text] [Related]
23. Adherence to Adjuvant Endocrine Therapy in Christchurch Women with Early Breast Cancer.
Robinson B; Dijkstra B; Davey V; Tomlinson S; Frampton C
Clin Oncol (R Coll Radiol); 2018 Jan; 30(1):e9-e15. PubMed ID: 29103853
[TBL] [Abstract][Full Text] [Related]
24. Adherence status to Adjuvant Endocrine Therapy in Chinese Women with Early Breast Cancer and its influencing factors: A cross-sectional survey.
Xu H; Jin F; Zhang XJ; Wang DQ; Yu SF; Wang AP
Cancer Med; 2020 Jun; 9(11):3703-3713. PubMed ID: 32237070
[TBL] [Abstract][Full Text] [Related]
25. Adherence to long-term adjuvant hormonal therapy for breast cancer.
Gotay C; Dunn J
Expert Rev Pharmacoecon Outcomes Res; 2011 Dec; 11(6):709-15. PubMed ID: 22098287
[TBL] [Abstract][Full Text] [Related]
26. Factors influencing the use of extended adjuvant endocrine therapy.
Kadakia KC; Kidwell KM; Barton DL; Schott AF; Hayes DF; Griggs JJ; Henry NL
Breast Cancer Res Treat; 2019 May; 175(1):181-189. PubMed ID: 30706190
[TBL] [Abstract][Full Text] [Related]
27. Managing side effects in adjuvant endocrine therapy for breast cancer.
Condorelli R; Vaz-Luis I
Expert Rev Anticancer Ther; 2018 Nov; 18(11):1101-1112. PubMed ID: 30188738
[TBL] [Abstract][Full Text] [Related]
28. Adjuvant Endocrine Therapy for Hormone-positive Breast Cancer, Focusing on Ovarian Suppression and Extended Treatment: An Update.
Glassman D; Hignett S; Rehman S; Linforth R; Salhab M
Anticancer Res; 2017 Oct; 37(10):5329-5341. PubMed ID: 28982841
[TBL] [Abstract][Full Text] [Related]
29. Navigating the Challenges of Endocrine Treatments in Premenopausal Women with ER-Positive Early Breast Cancer.
Colleoni M; Munzone E
Drugs; 2015 Aug; 75(12):1311-21. PubMed ID: 26177891
[TBL] [Abstract][Full Text] [Related]
30. Psychosocial factors related to non-persistence with adjuvant endocrine therapy among women with breast cancer: the Breast Cancer Quality of Care Study (BQUAL).
Hershman DL; Kushi LH; Hillyer GC; Coromilas E; Buono D; Lamerato L; Bovbjerg DH; Mandelblatt JS; Tsai WY; Zhong X; Jacobson JS; Wright JD; Neugut AI
Breast Cancer Res Treat; 2016 May; 157(1):133-43. PubMed ID: 27086286
[TBL] [Abstract][Full Text] [Related]
31. Factors associated with endocrine therapy adherence among post-menopausal women treated for early-stage breast cancer in Ontario, Canada.
Blanchette PS; Lam M; Richard L; Allen B; Shariff SZ; Vandenberg T; Pritchard KI; Chan KKW; Louie AV; Desautels D; Raphael J; Earle CC
Breast Cancer Res Treat; 2020 Jan; 179(1):217-227. PubMed ID: 31571072
[TBL] [Abstract][Full Text] [Related]
32. Adherence to adjuvant endocrine therapy in estrogen receptor-positive breast cancer patients with regular follow-up.
Simon R; Latreille J; Matte C; Desjardins P; Bergeron E
Can J Surg; 2014 Feb; 57(1):26-32. PubMed ID: 24461223
[TBL] [Abstract][Full Text] [Related]
33. Drug switch because of treatment-related adverse side effects in endocrine adjuvant breast cancer therapy: how often and how often does it work?
Güth U; Myrick ME; Schötzau A; Kilic N; Schmid SM
Breast Cancer Res Treat; 2011 Oct; 129(3):799-807. PubMed ID: 21750963
[TBL] [Abstract][Full Text] [Related]
34. Understanding Breast Cancer Survivors' Beliefs and Concerns About Adjuvant Hormonal Therapy: Promoting Adherence.
Hurtado-de-Mendoza A; Jensen RE; Jennings Y; Sheppard VB
J Cancer Educ; 2018 Apr; 33(2):436-439. PubMed ID: 28205022
[TBL] [Abstract][Full Text] [Related]
35. Adjuvant therapy use among Appalachian breast cancer survivors.
Tan X; Marshall VD; Anderson RT; Donohoe J; Camacho F; Balkrishnan R
Medicine (Baltimore); 2015 Jul; 94(26):e1071. PubMed ID: 26131828
[TBL] [Abstract][Full Text] [Related]
36. Simulating Time-Dependent Patterns of Nonadherence by Patients With Breast Cancer to Adjuvant Oral Endocrine Therapy.
Shinn EH; Broderick G; Fellman B; Johnson A; Wieland E; Moulder S; Symmans WF
JCO Clin Cancer Inform; 2019 Apr; 3():1-9. PubMed ID: 31002563
[TBL] [Abstract][Full Text] [Related]
37. Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review.
Murphy CC; Bartholomew LK; Carpentier MY; Bluethmann SM; Vernon SW
Breast Cancer Res Treat; 2012 Jul; 134(2):459-78. PubMed ID: 22689091
[TBL] [Abstract][Full Text] [Related]
38. Adherence rates and correlates in long-term hormonal therapy.
Dunn J; Gotay C
Vitam Horm; 2013; 93():353-75. PubMed ID: 23810015
[TBL] [Abstract][Full Text] [Related]
39. Predicting nonadherence to adjuvant endocrine therapy in women with early stage breast cancer.
Corter AL; Broom R; Porter D; Harvey V; Findlay M
Psychooncology; 2018 Sep; 27(9):2096-2103. PubMed ID: 29776011
[TBL] [Abstract][Full Text] [Related]
40. The Patient's Voice: Adherence, Symptoms, and Distress Related to Adjuvant Endocrine Therapy After Breast Cancer.
Jacobs JM; Walsh EA; Park ER; Berger J; Peppercorn J; Partridge A; Horick N; Safren SA; Temel JS; Greer JA
Int J Behav Med; 2020 Dec; 27(6):687-697. PubMed ID: 32495240
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]